Overview of Neurolep

Property	Description
Active ingredient	Piracetam
Form	Tablet and Oral Solution
Pharmacological class	Nootropic Drug, Psychotropic Agent
General purpose	To modulate cognitive function
Origin	Synthetic organic compound

What Type of Medicine is Neurolep and What is its Active Ingredient?

Neurolep is a pharmaceutical product primarily defined by its active ingredient, Piracetam, which places it within the racetam class of compounds and classifies it as a nootropic drug. Piracetam is a synthetic organic compound structurally related to gamma-aminobutyric acid (GABA), yet its mechanism of action is distinct from traditional GABA-related substances. Neurolep is a single-ingredient product categorized as a psychotropic agent designed to act on the central nervous system. The nootropic designation means the medicine focuses on influencing and supporting cognitive processes without producing the general sedation or pronounced stimulation seen with other types of psychotropic agents.

What is the General Purpose of Nootropic Drugs like Neurolep?

Stemming from its nootropic profile, the general purpose of Neurolep is to modulate cognitive function and support mental efficiency. Piracetam's established mechanism includes actions that grant it the classification of a haemorrheological agent, meaning it positively influences blood components to enhance microcirculation within the brain. This action involves Piracetam's role in optimizing the delivery of resources to neurons. Furthermore, it is known to exhibit a neuroprotective capacity by helping to stabilize neuronal membranes, supporting the overall goal of the medicine to enhance mental clarity and memory processes.

In What Dosage Forms is Neurolep Available?

Neurolep, containing Piracetam, is typically supplied for oral administration in two main dosage forms: a Tablet and an Oral Solution. The Oral Solution uses an aqueous base, which can be an advantage for individuals who may have difficulty swallowing tablets, while the Tablet form relies on solid excipients to deliver a convenient, solid dose. The availability of these distinct preparations ensures the medicinal entity can be delivered effectively according to the needs of the patient.

What side effects are possible with Neurolep?

Possible Side Effects and Safety Information

The regulatory profile of Neurolep, defined by its active ingredient Piracetam, documents adverse reactions that are classified by frequency and the physiological systems they affect. This information is consistent with official governmental prescribing information, such as the Summary of Product Characteristics (SmPC).

Adverse reactions that are Common (occurring in ge 1/100 to < 1/10 patients) include nervousness, weight increase, and hyperkinesia (increased muscular activity). Reactions classified as Uncommon include somnolence and asthenia (physical weakness).

System Organ Classes and Serious Reactions

Adverse events are grouped into System Organ Classes (SOCs). Documented effects involve Nervous System Disorders, Psychiatric Disorders (e.g., agitation, insomnia), Gastrointestinal Disorders (e.g., diarrhoea, nausea), and Skin and Subcutaneous Tissue Disorders.

Serious adverse reactions explicitly noted in regulatory documents, classified as frequency Not Known, include anaphylactoid reaction (a severe generalized hypersensitivity event) and angioneurotic oedema (severe localized swelling). There is also a documented safety concern regarding an increased bleeding tendency, particularly when used with anticoagulants.

Safety Considerations for Specific Populations

Official safety statements require special attention to certain patient populations. Neurolep is contraindicated in individuals with severe renal impairment (kidney dysfunction). Caution is necessary in all patients with pre-existing renal issues and in older adults, where dose adjustment based on assessed renal function is generally recommended. Caution is also necessary in patients with pre-existing haemostatic problems or those undergoing major surgery due to the documented risk of increased bleeding tendency.

Overdose and Emergency Response

Overdose and When to Seek Help

This information describes the documented manifestations and mandated emergency procedures for Neurolep (Piracetam) overdose, strictly based on regulatory prescribing information.

Documented Manifestations and Scope

Overdose cases involving piracetam are classified as rare, with regulatory reports noting a highest known oral intake of 75 grams. The documented clinical manifestations observed in these situations are primarily gastrointestinal, including diarrhea and abdominal pain; bloody diarrhea was reported in one single case.

Official regulatory summaries explicitly state that these symptoms are considered most probably related to the presence of a high dose of the sorbitol excipient in the formulation, rather than to the active substance itself.

Required Emergency Actions

It is mandated that patients should seek medical advice for the management of an overdose situation. Due to the officially documented absence of a specific antidote for piracetam, management focuses entirely on supportive care.

For cases of acute, significant overdosage, stomach emptying procedures are officially recommended. These supportive measures may include gastric lavage or induced emesis. Treatment is centered on providing symptomatic treatment and supportive therapy. If required, management may include hemodialysis, which has a documented piracetam extraction efficiency of 50% to 60%.

Therapeutic Uses of Neurolep

What Neurolep Treats: Main Uses and Benefits

The primary role of Neurolep (Piracetam) is to provide symptomatic support across domains where neurological and cognitive functions are compromised, and contributes to easing the overall symptom load. This medication is applicable in clinical settings that involve acute or disruptive symptom patterns.

This medication is generally applied in situations where patients experience symptoms related to age-related involution syndrome, deficits in memory, asthenia, and adaptation disorders. It is relevant when symptoms create noticeable interference with daily comfort, such as difficulties with focus and general psychomotor reaction. The specific indications where Neurolep is commonly used include cortical myoclonus, vertigo, specific learning difficulties like dyslexia, and is used for managing the symptoms of vaso-occlusive crises in sickle cell disease.

“Neurolep provides support that helps ease the overall symptom burden when symptoms become more noticeable.”

It is applied across domains where additional symptomatic support is needed for managing conditions presenting with disruptive symptom manifestations, such as involuntary muscle movements or post-traumatic memory issues. This support may assist with maintaining functional stability and contributes to easing the overall symptom load during episodes of heightened discomfort.

Quick Fact: Support for Symptom Fluctuations

Neurolep contributes to improved comfort during symptomatic periods by addressing cognitive deficits and helping to moderate symptoms like unsteadiness and certain muscle jerks, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

Indonesian Drug Regulatory Authority (Badan POM) product assessment for Nootropil™

Eligibility and Restrictions for Use

Who can and cannot use Neurolep?

The eligibility for Neurolep (Piracetam) is strictly defined by regulatory documents, which establish clear contraindications and conditional use populations.

Absolute Contraindications

Neurolep is formally contraindicated and must not be used by patients with cerebral haemorrhage, End-Stage Renal Disease (ESRD), or severe renal impairment (Creatinine Clearance < 20 ml/min). Use is also prohibited for patients suffering from Huntington's Chorea or those with a known hypersensitivity to piracetam or other pyrrolidone derivatives.

Restricted and Conditional Use

Use is conditional for patients with mild to moderate renal impairment (CrCl ge 20 to 79 ml/min), which requires mandatory dose individualisation. Caution is recommended for patients with a high risk of bleeding, such as those with underlying haemostasis disorders, due to the drug's effect on platelet aggregation. Older adults on long-term treatment require regular evaluation of creatinine clearance.

Pregnancy and Age Restrictions

The medicine should not be used during pregnancy or breastfeeding unless deemed clearly necessary, and breastfeeding must be discontinued while on treatment. Use in children and adolescents under 16 years of age is generally not recommended. Patients with solely hepatic impairment may use the medicine without dose adjustment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Neurolep (Piracetam) is characterized by specific documented pharmacodynamic interactions and a low potential for metabolic pharmacokinetic interference, as confirmed in government regulatory documents.

Pharmacodynamic Interaction Patterns

Co-administration with Thyroid Hormones ( T3 and T4) has been officially reported to result in clinical manifestations such as confusion, irritability, and sleep disorder.

Additionally, use with oral anticoagulants, such as Acenocoumarol, results in an observed pharmacodynamic reinforcement. Regulatory studies show that co-administration significantly decreased platelet aggregation when compared to the anticoagulant used alone, confirming an additive anti-aggregatory effect.

Pharmacokinetic and Consumption Findings

The potential for Neurolep to cause pharmacokinetic drug interactions is considered low. This is primarily due to its elimination route, as approximately ninety percent of the dose is excreted via the kidneys as unchanged drug, minimizing interaction risks with the body’s major metabolic enzymes. Official studies confirm that the medicine does not inhibit major Cytochrome P450 (CYP) isoforms, and co-administration did not modify the serum levels of anti-epileptic drugs like Carbamazepine.

Furthermore, co-administration of alcohol has no documented effect on the medicine's serum levels, nor does the medicine modify alcohol levels. The oral solution dosage form may be taken with or without food, as there are no specified timing or dietary restrictions documented in the product's official labeling.

Mechanism of Action

Cellular Membrane Fluidity and Neuronal Stabilization

The primary action of Neurolep (Piracetam) involves the modulation of the phospholipid bilayer in neuronal and erythrocyte cell membranes. By physically integrating into the membrane, the drug influences its fluidity, which in turn affects the function of embedded transmembrane proteins like receptors and ion channels. This fundamental action contributes to the maintenance of neuronal functional integrity.

Indirect Modulation of Neurotransmission

This mechanism is a direct consequence of membrane modulation, leading to the indirect influence on crucial cholinergic and glutamatergic neurotransmission pathways. By affecting receptor function, Neurolep supports communication across synapses and affects the functional dynamics required for interhemispheric information transfer. This action is mechanistically linked to pathways involved in CNS information processing.

Modulation of Cerebral Microcirculation

Neurolep also acts as a haemorheological agent by modulating the flow properties of blood. This effect is achieved by increasing the deformability of red blood cells and reducing their aggregation and adhesion within the microvasculature. The resulting change in blood flow properties affects cerebral microcirculation, which facilitates the delivery of oxygen and glucose. This physiological support complements the drug's direct molecular effects on neuronal function.

Dosage and Administration Information

How to Use Neurolep: Official Administration Guidelines

Neurolep (Piracetam) is approved for administration via two primary routes: oral (using tablets or solutions) and intravenous (IV). The oral forms may be taken with or without food. When administered intravenously, the solution may be given as a slow injection over several minutes or as a continuous infusion over a 24-hour period.

Dosage and Frequency

The standard daily dose for general use ranges from 2.4 g up to 4.8 g, which is typically administered in two to four equally divided sub-doses. For conditions requiring higher doses, such as cortical myoclonus, treatment begins at 7.2 g daily. The dose is incrementally increased by 4.8 g every three to four days up to a maximum of 24 g daily, administered in two or three doses.

Population-Specific Adjustments

Mandatory dose adjustments are required for patients with compromised renal function due to the drug’s elimination pathway. The required dosage is calculated based on Creatinine Clearance (CLcr):

Renal Function (CLcr ml/min)	Recommended Dose Adjustment
Mild (50–79)	2/3 of the usual daily dose
Moderate (30–49)	1/3 of the usual daily dose
Severe (< 30)	1/6 of the usual daily dose (single intake)

No dose adjustment is required for solely hepatic impairment. In pediatric patients receiving treatment for sickle cell disease, the dose is determined based on body weight.

Discontinuation and Missed Doses

Treatment must not be stopped abruptly. The dose should be gradually reduced by 1.2 g every two days to prevent a sudden return of symptoms. Treatment should be continued for as long as the original condition persists, with attempts to discontinue reviewed every 6 months. If a dose is missed, instructions state to continue with the next scheduled dose without doubling the amount.

Recent Clinical Evidence

Neurolep: Recent Clinical Evidence

Neurolep (Piracetam) has been evaluated in research exploring its profile through various trial designs, including controlled clinical trials and systematic reviews of existing data. The available evidence base is varied, and findings across different indications reflect different data structures. Research provides context, but does not determine whether an individual will respond similarly.

Evidence for use in Cognitive Deficits and Age-Related Symptoms

Research was studied for trials exploring its role in conditions characterized by fluctuating or episodic manifestations of cognitive difficulties, memory deficits, asthenia (physical weakness or lack of energy), and other symptoms related to age-related changes. These studies primarily included older adults and geriatric patients with age-related cognitive impairment.

Findings describe patterns observed in the studies where certain short-term memory and attention tasks reported measured shifts compared to control groups. Evidence across systematic reviews was noted to be heterogeneous, meaning results varied substantially between individual trials. Furthermore, much of the research base describes the use of historical methodologies that are often less sophisticated than contemporary trial designs.

Evidence for use in Movement Disorders and Balance Deficits

Neurolep was studied for conditions associated with acute or disruptive episodes, specifically involuntary muscle movements (cortical myoclonus) and certain balance deficits (vertigo). Studies explored patient populations with cortical myoclonus, where certain involuntary muscle movements were monitored for changes. For balance issues, research explores the measurement of changes in symptom intensity and associated functional changes.

What is Still Uncertain About Neurolep Research

The research landscape contains several known limitations. The follow-up durations were limited in many controlled trials, providing limited insight into the sustained nature of changes. The evidence quality varies across studies, and the sample sizes were modest in some original studies. Long-term effects are not fully established, and certainty remains low for broad conclusions regarding the durability of any observed effects.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Neurolep (FAQ)

Q: How long does it typically take to start feeling the effects of Neurolep?

Official information from the regulatory profile primarily describes the medicine's mechanism of action, such as its effects on cell membranes and neurochemical processes, rather than a specific time to feel the general effects. In research studies related to certain acute uses (extrapyramidal side effects), the onset of action was observed to be between 30 and 60 minutes after intravenous administration.

Q: Does Neurolep interact with blood pressure medication?

Official drug documents do not list specific interactions with common blood pressure medications. The product information indicates a low potential for many pharmacokinetic drug interactions because the medicine is primarily eliminated via the kidneys, minimizing risk with the body's major metabolic enzymes.

Q: Can Neurolep cause dizziness or lightheadedness?

Yes, official safety data confirms that dizziness-related symptoms are documented adverse reactions. The adverse reaction profile includes reports of vertigo (a sensation of spinning or dizziness) and balance impaired in the 'Not Known' frequency category. Dizziness is also listed as a common side effect in some official summaries.

Q: Why is Neurolep sometimes referred to as a mood stabilizer?

Official classification defines Neurolep, whose active ingredient is Piracetam, as a nootropic drug and a psychotropic agent intended to modulate cognitive function. The medicine is classified differently from a 'mood stabilizer,' a term not used in the official regulatory labeling for this medicine.

Q: What is the main difference between Neurolep and other similar medicines?

Official sources describe Neurolep as the first nootropic drug in the racetam class of compounds. Its unique mechanism of action is defined by the modulation of neuronal and red blood cell membranes, a process that is separate from traditional GABAA-related substances. It is also noted to have the regulatory classifications of a neuroprotective and haemorheological agent (influencing blood flow properties).

Q: Can Neurolep affect my sleep patterns?

Yes, official safety documents confirm that the medicine may affect sleep. The adverse reaction profile lists both somnolence (drowsiness/sleepiness) as an uncommon side effect and insomnia (difficulty sleeping) as a side effect with a frequency of 'Not Known.'

Q: Is it safe to drive while taking Neurolep?

Official warnings state that the medicine may cause side effects such as drowsiness and shakiness (or somnolence). The product labeling indicates that individuals should refrain from driving or using machinery if they experience these documented adverse reactions.

Q: What are the long-term risks associated with taking Neurolep?

The official safety profile documents potential safety concerns, such as an increased bleeding tendency and severe hypersensitivity reactions. For patients on long-term treatment, particularly older adults, official documents state that regular evaluation of creatinine clearance (kidney function) is required for appropriate dose adjustment.

Q: Is Neurolep a controlled substance?

Official government drug schedules provide the regulatory classification for the active ingredient. The medicine is not classified as a federally controlled substance in the United States and is not scheduled in many other jurisdictions where it is approved or available.

Q: Does Neurolep cause sexual side effects?

Some adverse event reporting in regulatory summaries does note sexual-related effects. These include reports of increased libido and hypersexuality, which are generally noted as documented but infrequently reported side effects.

Q: Does Neurolep affect memory or focus?

The general purpose of the drug is defined in official documents as supporting and modulating cognitive function and memory processes. However, official regulatory safety documentation does not list impaired memory or impaired focus as documented negative side effects.

Q: What kind of monitoring is typically required while taking Neurolep?

Official documents require specific monitoring for certain populations. For patients with renal (kidney) impairment and older adults on long-term treatment, a regular evaluation of creatinine clearance is necessary to allow for mandatory dose adjustments.

Q: Is Neurolep connected to any warnings for pregnant women?

Yes, official warnings state that the medicine crosses the placental barrier and should not be used during pregnancy unless a healthcare provider deems it clearly necessary. Drug levels in the newborn are noted to be approximately 70% to 90% of maternal levels.

Q: Can Neurolep cause problems with my liver or kidneys?

Caution is specifically required for kidney function because the drug is primarily eliminated via the kidneys, and its use is contraindicated in severe renal impairment. Conversely, the official labeling states that the medicine does not require dose adjustment for patients with solely hepatic (liver) impairment.

Q: Is it normal to feel tired when first starting Neurolep?

The adverse reaction profile includes somnolence (drowsiness/sleepiness) and asthenia (physical weakness or lack of energy) as documented, though uncommon, side effects. This confirms that tiredness-related feelings are reported adverse reactions that may be experienced when beginning treatment.

Q: Are there any severe but rare side effects of Neurolep?

Yes, official regulatory documents explicitly note the potential for anaphylactoid reaction (a severe generalized allergic reaction) and angioneurotic oedema (severe localized swelling) in the adverse reactions section, with a frequency classified as 'Not Known' (implying rare occurrence).

Q: Why are people concerned about movement disorders when taking Neurolep?

Concerns relate to documented adverse reactions, which include the Common side effect hyperkinesia (increased muscular activity) and the 'Not Known' frequency reactions ataxia (lack of voluntary coordination) and balance impaired. These are all specific types of movement-related effects listed in the safety profile.

How should Neurolep be stored and disposed of?

How to Store and Dispose of Neurolep (Piracetam)

Official regulatory guidelines specify precise conditions for storing and disposing of Neurolep to maintain stability and safety.

Storage Requirements

Temperature and Environment: The medicine must be stored at a temperature below 30 C in a dry place. It is necessary to protect the product from excessive heat and freezing, and it must be kept in the original container.
Child Safety: It is mandatory that Neurolep is stored out of the sight and reach of children at all times.
Expiration: The product must not be used after the expiry date printed on the packaging, even if stored correctly.

Disposal Instructions

Official disposal protocols require that the medication must not be thrown away via wastewater or household waste. Patients should consult a pharmacist for guidance on proper disposal, such as a medicine take-back program. If the original container is discarded, all identifying information must be scratched out to protect personal health information.

Neurolep